Kazumi Tanaka1, Kimihiro Shimizu1, Seiichi Kakegawa1, Yoichi Ohtaki1, Toshiteru Nagashima1, Kyoichi Kaira2, Jun Horiguchi1, Tetsunari Oyama3, Izumi Takeyoshi1. 1. Department of Thoracic and Visceral Organ Surgery, Graduate School of Medicine, Gunma University 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. 2. Department of Medicine and Molecular Science, Graduate School of Medicine, Gunma University 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. 3. Department of Division of Diagnostic Pathology, Graduate School of Medicine, Gunma University 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan.
Abstract
OBJECTIVES: Based on recent findings of aromatase and estrogen receptor beta (ERβ) expression in non-small-cell lung cancer, we assessed the clinicopathological and prognostic significance of aromatase and ERβ expression and their relationship to epidermal growth factor receptor (EGFR) mutation in lung adenocarcinoma. MATERIALS AND METHODS: We evaluated 150 resected primary lung adenocarcinoma specimens. Expression of aromatase, ERα, ERβ, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was evaluated by immunostaining, and EGFR and KRAS mutations were analyzed. Overall survival (OS) and recurrence-free survival (RFS) were calculated using the Kaplan-Meier method. RESULTS: Expression of aromatase, ERα, ERβ, PR, and HER2 was detected in 88.0%, 1.3%, 79.3%, 2.7%, and 39.3% of specimens, respectively. In patients with EGFR wild-type lung adenocarcinoma, high aromatase expression was an independent predictor of poor OS (hazard ratio [HR]=2.638; 95% confidence interval [CI], 1.173-5.936; P=.019) and RFS (HR=2.505; 95% CI, 1.154-5.434; P=.020). Positive ERβ expression was also an independent predictor of poor RFS (HR=4.013; 95% CI, 1.219-13.207; P=.022). Furthermore, high aromatase expression was a significant predictor of poor survival only in females (OS, P=.010; RFS, P=.007), whereas positive ERβ expression was an important predictor of poor survival only in males (OS, P=.073; RFS, P=.051). No prognostic significance was observed in patients with EGFR mutations. CONCLUSIONS: Our findings suggest that EGFR wild-type lung adenocarcinoma is an estrogen-dependent carcinoma, and aromatase expression and ERβ expression are potent prognostic markers for EGFR wild-type lung adenocarcinoma.
OBJECTIVES: Based on recent findings of aromatase and estrogen receptor beta (ERβ) expression in non-small-cell lung cancer, we assessed the clinicopathological and prognostic significance of aromatase and ERβ expression and their relationship to epidermal growth factor receptor (EGFR) mutation in lung adenocarcinoma. MATERIALS AND METHODS: We evaluated 150 resected primary lung adenocarcinoma specimens. Expression of aromatase, ERα, ERβ, progesterone receptor (PR), and humanepidermal growth factor receptor 2 (HER2) was evaluated by immunostaining, and EGFR and KRAS mutations were analyzed. Overall survival (OS) and recurrence-free survival (RFS) were calculated using the Kaplan-Meier method. RESULTS: Expression of aromatase, ERα, ERβ, PR, and HER2 was detected in 88.0%, 1.3%, 79.3%, 2.7%, and 39.3% of specimens, respectively. In patients with EGFR wild-type lung adenocarcinoma, high aromatase expression was an independent predictor of poor OS (hazard ratio [HR]=2.638; 95% confidence interval [CI], 1.173-5.936; P=.019) and RFS (HR=2.505; 95% CI, 1.154-5.434; P=.020). Positive ERβ expression was also an independent predictor of poor RFS (HR=4.013; 95% CI, 1.219-13.207; P=.022). Furthermore, high aromatase expression was a significant predictor of poor survival only in females (OS, P=.010; RFS, P=.007), whereas positive ERβ expression was an important predictor of poor survival only in males (OS, P=.073; RFS, P=.051). No prognostic significance was observed in patients with EGFR mutations. CONCLUSIONS: Our findings suggest that EGFR wild-type lung adenocarcinoma is an estrogen-dependent carcinoma, and aromatase expression and ERβ expression are potent prognostic markers for EGFR wild-type lung adenocarcinoma.
Authors: E R Simpson; M S Mahendroo; G D Means; M W Kilgore; M M Hinshelwood; S Graham-Lorence; B Amarneh; Y Ito; C R Fisher; M D Michael Journal: Endocr Rev Date: 1994-06 Impact factor: 19.871
Authors: Ann G Schwartz; Geoffrey M Prysak; Valerie Murphy; Fulvio Lonardo; Harvey Pass; Jan Schwartz; Sam Brooks Journal: Clin Cancer Res Date: 2005-10-15 Impact factor: 12.531
Authors: Sofia K Gruvberger-Saal; Pär-Ola Bendahl; Lao H Saal; Mervi Laakso; Cecilia Hegardt; Patrik Edén; Carsten Peterson; Per Malmström; Jorma Isola; Ake Borg; Mårten Fernö Journal: Clin Cancer Res Date: 2007-04-01 Impact factor: 12.531
Authors: Laura P Stabile; Autumn L Gaither Davis; Christopher T Gubish; Toni M Hopkins; James D Luketich; Neil Christie; Sydney Finkelstein; Jill M Siegfried Journal: Cancer Res Date: 2002-04-01 Impact factor: 12.701
Authors: Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano Journal: Front Pharmacol Date: 2018-09-19 Impact factor: 5.810